Axsome Therapeutics Acquires Baergic Bio and Global Rights to BAER-101 from Avenue Therapeutics

Reuters11-12

Axsome <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Acquires Baergic Bio and Global Rights to BAER-101 from Avenue Therapeutics

Avenue Therapeutics' majority-owned subsidiary, Baergic Bio, is being acquired by Axsome Therapeutics, which will receive global rights to BAER-101 (also known as AZD7325), a novel oral GABAA α2,3 receptor modulator. Under the terms of the agreement, Baergic Bio shareholders are set to receive a $0.3 million upfront payment (less transaction expenses), with eligibility for milestone payments of up to $2.5 million for the first indication and $1.5 million for each additional indication. The deal also includes up to $79 million in potential sales-based milestones and a tiered mid-to-high single-digit royalty on global net sales of AXS-17. Avenue is expected to receive approximately 74% of all future payments and royalties under the agreement. Axsome plans to advance AXS-17 in epilepsy, leveraging anti-convulsant effects observed in preclinical models.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avenue Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-25-034243), on November 12, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2582730379?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-12 21:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582730379","market":"us","top_or_hot":-1,"title":"Axsome Therapeutics Acquires Baergic Bio and Global Rights to BAER-101 from Avenue Therapeutics","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Axsome <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Acquires Baergic Bio and Global Rights to BAER-101 from Avenue Therapeutics\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Avenue Therapeutics' majority-owned subsidiary, Baergic Bio, is being acquired by Axsome Therapeutics, which will receive global rights to BAER-101 (also known as AZD7325), a novel oral GABAA α2,3 receptor modulator. Under the terms of the agreement, Baergic Bio shareholders are set to receive a $0.3 million upfront payment (less transaction expenses), with eligibility for milestone payments of up to $2.5 million for the first indication and $1.5 million for each additional indication. The deal also includes up to $79 million in potential sales-based milestones and a tiered mid-to-high single-digit royalty on global net sales of AXS-17. Avenue is expected to receive approximately 74% of all future payments and royalties under the agreement. Axsome plans to advance AXS-17 in epilepsy, leveraging anti-convulsant effects observed in preclinical models.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avenue Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-25-034243), on November 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Axsome Therapeutics Acquires Baergic Bio and Global Rights to BAER-101 from Avenue Therapeutics</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAxsome Therapeutics Acquires Baergic Bio and Global Rights to BAER-101 from Avenue Therapeutics\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-12 21:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Axsome <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Acquires Baergic Bio and Global Rights to BAER-101 from Avenue Therapeutics\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Avenue Therapeutics' majority-owned subsidiary, Baergic Bio, is being acquired by Axsome Therapeutics, which will receive global rights to BAER-101 (also known as AZD7325), a novel oral GABAA α2,3 receptor modulator. Under the terms of the agreement, Baergic Bio shareholders are set to receive a $0.3 million upfront payment (less transaction expenses), with eligibility for milestone payments of up to $2.5 million for the first indication and $1.5 million for each additional indication. The deal also includes up to $79 million in potential sales-based milestones and a tiered mid-to-high single-digit royalty on global net sales of AXS-17. Avenue is expected to receive approximately 74% of all future payments and royalties under the agreement. Axsome plans to advance AXS-17 in epilepsy, leveraging anti-convulsant effects observed in preclinical models.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avenue Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-25-034243), on November 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDL6dDB3Y:1","article_id":"2582730379","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582730379","pubTimestamp":1762952581,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Avenue Therapeutics' majority-owned subsidiary, Baergic Bio, is being acquired by Axsome Therapeutics, which will receive global rights to BAER-101 , a novel oral GABAA α2,3 receptor modulator. Under the terms of the agreement, Baergic Bio shareholders are set to receive a $0.3 million upfront payment , with eligibility for milestone payments of up to $2.5 million for the first indication and $1.5 million for each additional indication. The deal also includes up to $79 million in potential sales-based milestones and a tiered mid-to-high single-digit royalty on global net sales of AXS-17. Avenue is expected to receive approximately 74% of all future payments and royalties under the agreement. Axsome plans to advance AXS-17 in epilepsy, leveraging anti-convulsant effects observed in preclinical models.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","FBIO":"Fortress Biotech Inc.","BK4585":"ETF&股票定投概念","BK4505":"高瓴资本持仓","ATXI":"Avenue Therapeutics, Inc.","BK4139":"生物科技","AXSM":"Axsome Therapeutics, Inc."},"translate_title":"Axsome Therapeutics从Avenue Therapeutics收购Baergic Bio和BAER-101的全球权利","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AXSM":0.9,"FBIO":0.9,"ATXI":0.9},"content_text":"Axsome Therapeutics Acquires Baergic Bio and Global Rights to BAER-101 from Avenue Therapeutics\n    \n\n        Avenue Therapeutics' majority-owned subsidiary, Baergic Bio, is being acquired by Axsome Therapeutics, which will receive global rights to BAER-101 (also known as AZD7325), a novel oral GABAA α2,3 receptor modulator. Under the terms of the agreement, Baergic Bio shareholders are set to receive a $0.3 million upfront payment (less transaction expenses), with eligibility for milestone payments of up to $2.5 million for the first indication and $1.5 million for each additional indication. The deal also includes up to $79 million in potential sales-based milestones and a tiered mid-to-high single-digit royalty on global net sales of AXS-17. Avenue is expected to receive approximately 74% of all future payments and royalties under the agreement. Axsome plans to advance AXS-17 in epilepsy, leveraging anti-convulsant effects observed in preclinical models.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avenue Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-25-034243), on November 12, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.10","shortVersion":"4.35.10","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2582730379","isCrawlerRequest":true}